[go: up one dir, main page]

MX2019010370A - Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes. - Google Patents

Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes.

Info

Publication number
MX2019010370A
MX2019010370A MX2019010370A MX2019010370A MX2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A
Authority
MX
Mexico
Prior art keywords
purified
compositions
cannabinoids
terpenes
compositions comprise
Prior art date
Application number
MX2019010370A
Other languages
Spanish (es)
Inventor
Michael Cooper Jonathan
Levy Kurt
Reed Martin Jonathan
Geoffrey Reid Brian
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/616,874 external-priority patent/US20170266153A1/en
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of MX2019010370A publication Critical patent/MX2019010370A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

En este documento se divulgan nuevas composiciones que comprenden un cannabinoide purificado y un terpeno purificado. En una realizacion, las composiciones comprenden uno o mas cannabinoides purificados. En una realizacion, las composiciones comprenden uno o mas cannabinoides purificados en combinacion con uno o mas terpenos purificados. En una realizacion, las composiciones comprenden proporciones no naturales. En una realizacion, las composiciones comprenden concentraciones no naturales. En una realizacion, las composiciones comprenden efectos inesperados y/o sinergicos.New compositions comprising a purified cannabinoid and a purified terpene are disclosed herein. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnatural proportions. In one embodiment, the compositions comprise unnatural concentrations. In one embodiment, the compositions comprise unexpected and / or synergistic effects.

MX2019010370A 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes. MX2019010370A (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201762465688P 2017-03-01 2017-03-01
US201762469415P 2017-03-09 2017-03-09
US201762475153P 2017-03-22 2017-03-22
US201762477990P 2017-03-28 2017-03-28
US201762489360P 2017-04-24 2017-04-24
US201762490567P 2017-04-26 2017-04-26
US201762490465P 2017-04-26 2017-04-26
US201762491160P 2017-04-27 2017-04-27
US201762491175P 2017-04-27 2017-04-27
US201762491899P 2017-04-28 2017-04-28
US201762491980P 2017-04-28 2017-04-28
US201762509651P 2017-05-22 2017-05-22
US201762510229P 2017-05-23 2017-05-23
US201762510660P 2017-05-24 2017-05-24
US201762510672P 2017-05-24 2017-05-24
US201762511218P 2017-05-25 2017-05-25
US15/616,874 US20170266153A1 (en) 2015-02-27 2017-06-07 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
PCT/US2018/020440 WO2018160827A1 (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes

Publications (1)

Publication Number Publication Date
MX2019010370A true MX2019010370A (en) 2019-10-22

Family

ID=63370542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010370A MX2019010370A (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes.

Country Status (10)

Country Link
EP (1) EP3589129A4 (en)
CN (1) CN110582206A (en)
AU (1) AU2018227544A1 (en)
BR (1) BR112019018088A2 (en)
CA (1) CA3054690A1 (en)
CO (1) CO2019009413A2 (en)
IL (1) IL268929A (en)
MX (1) MX2019010370A (en)
PE (1) PE20200383A1 (en)
WO (1) WO2018160827A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147690A1 (en) 2018-01-23 2019-08-01 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
IL266151A (en) * 2019-04-18 2019-07-31 Kanabo Res Ltd Diluents for compositions of cannabinoids
US11925907B2 (en) 2019-07-22 2024-03-12 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
BR112022010288A2 (en) * 2019-11-26 2022-09-27 Lycored Ltd SYNERGIC ANTI-INFLAMMATORY COMBINATIONS OF CANABINOID AND LYCOPENE
WO2021220208A1 (en) * 2020-04-29 2021-11-04 Ligar Limited Partnership Imprinted polymers and methods for their use
WO2022020944A1 (en) * 2020-07-27 2022-02-03 Canopy Growth Corporation Methods of synthesizing cannabielsoin and analogs thereof
WO2022165165A1 (en) * 2021-01-29 2022-08-04 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
CN113368086B (en) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 Cannabinoid composition and its application in preparation of medicine for treating neurodegenerative diseases such as Parkinson and Alzheimer
US20250367220A1 (en) * 2022-06-17 2025-12-04 New Growth Brands, Inc. Compositions comprising cannabinoids and methods of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019322A1 (en) * 2009-04-30 2010-11-11 The Health Concept Gmbh Process for the preparation of synthetic cannabinoids
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (en) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of plant cannabinoid cannabinol (CBDV) for the treatment of epilepsy
CA2931039C (en) * 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
CA2977802A1 (en) * 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral

Also Published As

Publication number Publication date
CO2019009413A2 (en) 2019-09-09
IL268929A (en) 2019-10-31
AU2018227544A1 (en) 2019-08-29
CN110582206A (en) 2019-12-17
CA3054690A1 (en) 2018-09-07
EP3589129A4 (en) 2020-11-25
EP3589129A1 (en) 2020-01-08
BR112019018088A2 (en) 2020-03-24
WO2018160827A1 (en) 2018-09-07
PE20200383A1 (en) 2020-02-24

Similar Documents

Publication Publication Date Title
MX2019010370A (en) Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes.
MX2017010872A (en) Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral.
CO2021005884A2 (en) Alpha-1 antitrypsin modulators
BR112017018276A2 (en) ? composition comprising peptidase and biotensive agent and their use?
CL2018002334A1 (en) Modulators of complements factor b (divisional application 201600606)
CL2019001187A1 (en) Fungicidal combinations
UY38798A (en) COMBINATIONS, MIXTURES AND FUNGICIDAL COMPOSITIONS AND USES OF THEM
ECSP19072372A (en) PCSK9 EXPRESSION MODULATORS
ECSP21026021A (en) PNPLA3 EXPRESSION MODULATORS
MX2018000412A (en) MODULATORS OF DIACIGLYCEROL ACILTRANSFERASA 2 (DGAT2).
CO2020001325A2 (en) Synergistic herbicidal combinations
MX2019006769A (en) COMPOSITIONS THAT INCLUDE SULPHATED POLYSACCHARIDES.
AR112015A1 (en) SOLID COMPOSITIONS FOR ORAL ADMINISTRATION
AR113419A1 (en) AEROSOLIZABLE FORMULATION
UY37977A (en) NEW COMBINATIONS OF DEFLOLIANTS
UY38284A (en) COMPOSITIONS AND METHODS TO AGONIZE THE CB2 RECEIVER
CO2019000604A2 (en) Vaginal composition comprising a combination of estrogen and vitamin D
MX2018007231A (en) AN ANTIMICROBIAL COMPOSITION.
CL2021001246A1 (en) Irf5 expression modulators.
MX2023008764A (en) Compositions and methods for preventing and treating conditions.
MX2020010424A (en) TABLET OR COMPOSITION CONTAINING N-ACYL ETHANOLAMINE AND CANNABINOIDS.
MX2018012377A (en) COMPOSITION.
JOP20190251A1 (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
AR110663A1 (en) COMPOSITION THAT INCLUDES HEMOCONCENTRATION REPLACEMENT FLUID
CO2020003134A2 (en) Modulators of enac expression